{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:31:10Z","timestamp":1785771070040,"version":"3.56.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,22]]},"DOI":"10.7759\/cureus.97523","type":"journal-article","created":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T03:44:32Z","timestamp":1763869472000},"source":"Crossref","is-referenced-by-count":1,"title":["Pharmacotherapy for Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome Beyond Conventional Laxatives: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Saroj K","family":"Sahu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preetam","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipadabhanjan","family":"Mallick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dibyalochan","family":"Praharaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suprabhat","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarat Chandra","family":"Panigrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil C.","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj K","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000614","article-title":"Chronic constipation in the United States: results from a population-based survey assessing healthcare seeking and use of pharmacotherapy","volume":"115","author":"Oh SJ","year":"2020","unstructured":"Oh SJ, Fuller G, Patel D, et al.. Chronic constipation in the United States: results from a population-based survey assessing healthcare seeking and use of pharmacotherapy. Am J Gastroenterol. 2020, 115:895-905. 10.14309\/ajg.0000000000000614","journal-title":"Am J Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002994","article-title":"Global prevalence and risk factors of irritable bowel syndrome from 2006 to 2024 using the Rome III and IV criteria: a meta-analysis","author":"Arif TB","year":"2025","unstructured":"Arif TB, Ali SH, Bhojwani KD, et al.. Global prevalence and risk factors of irritable bowel syndrome from 2006 to 2024 using the Rome III and IV criteria: a meta-analysis. Eur J Gastroenterol Hepatol. 2025, 10.1097\/MEG.0000000000002994","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s12664-018-0894-1","article-title":"Indian consensus on chronic constipation in adults: a joint position statement of the Indian Motility and Functional Diseases Association and the Indian Society of Gastroenterology","volume":"37","author":"Ghoshal UC","year":"2018","unstructured":"Ghoshal UC, Sachdeva S, Pratap N, et al.. Indian consensus on chronic constipation in adults: a joint position statement of the Indian Motility and Functional Diseases Association and the Indian Society of Gastroenterology. Indian J Gastroenterol. 2018, 37:526-44. 10.1007\/s12664-018-0894-1","journal-title":"Indian J Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5056\/jnm17112","article-title":"Lower and upper gastrointestinal symptoms differ between individuals with irritable bowel syndrome with constipation or chronic idiopathic constipation","volume":"24","author":"Shah ED","year":"2018","unstructured":"Shah ED, Almario CV, Spiegel BM, Chey WD. Lower and upper gastrointestinal symptoms differ between individuals with irritable bowel syndrome with constipation or chronic idiopathic constipation. J Neurogastroenterol Motil. 2018, 24:299-306. 10.5056\/jnm17112","journal-title":"J Neurogastroenterol Motil"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-019-0985-1","article-title":"Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries","volume":"19","author":"Tack J","year":"2019","unstructured":"Tack J, Stanghellini V, Mearin F, et al.. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries. BMC Gastroenterol. 2019, 19:69. 10.1186\/s12876-019-0985-1","journal-title":"BMC Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-023-04438-4","article-title":"Association between frailty and chronic constipation and chronic diarrhea among American older adults: National Health and Nutrition Examination Survey","volume":"23","author":"Liu X","year":"2023","unstructured":"Liu X, Wang Y, Shen L, Sun Y, Zeng B, Zhu B, Dai F. Association between frailty and chronic constipation and chronic diarrhea among American older adults: National Health and Nutrition Examination Survey. BMC Geriatr. 2023, 23:745. 10.1186\/s12877-023-04438-4","journal-title":"BMC Geriatr"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/164_2016_102","article-title":"Irritable bowel syndrome: pathophysiology and current therapeutic approaches","volume":"239","author":"Camilleri M","year":"2017","unstructured":"Camilleri M, Ford AC. Irritable bowel syndrome: pathophysiology and current therapeutic approaches. Handb Exp Pharmacol. 2017, 239:75-113. 10.1007\/164_2016_102","journal-title":"Handb Exp Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.10.029","article-title":"American Gastroenterological Association medical position statement on constipation","volume":"144","author":"Bharucha AE","year":"2013","unstructured":"Bharucha AE, Dorn SD, Lembo A, Pressman A. American Gastroenterological Association medical position statement on constipation. Gastroenterology. 2013, 144:211-7. 10.1053\/j.gastro.2012.10.029","journal-title":"Gastroenterology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2016.02.006","article-title":"Clinical practice guidelines for the management of constipation in adults. Part 1: definition, aetiology and clinical manifestations","volume":"40","author":"Serra J","year":"2017","unstructured":"Serra J, Mascort-Roca J, Marzo-Castillejo M, Delgado Aros S, Ferr\u00e1ndiz Santos J, Rey Diaz Rubio E, Mearin Manrique F. Clinical practice guidelines for the management of constipation in adults. Part 1: definition, aetiology and clinical manifestations. Gastroenterol Hepatol. 2017, 40:132-41. 10.1016\/j.gastrohep.2016.02.006","journal-title":"Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.54244","article-title":"The role of diet in the management of irritable bowel syndrome: a comprehensive review","volume":"16","author":"Jayasinghe M","year":"2024","unstructured":"Jayasinghe M, Karunanayake V, Mohtashim A, et al.. The role of diet in the management of irritable bowel syndrome: a comprehensive review. Cureus. 2024, 16:e54244. 10.7759\/cureus.54244","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00125.2021","article-title":"Contributions of bile acids to gastrointestinal physiology as receptor agonists and modifiers of ion channels","volume":"322","author":"Keely SJ","year":"2022","unstructured":"Keely SJ, Urso A, Ilyaskin AV, Korbmacher C, Bunnett NW, Poole DP, Carbone SE. Contributions of bile acids to gastrointestinal physiology as receptor agonists and modifiers of ion channels. Am J Physiol Gastrointest Liver Physiol. 2022, 322:G201-22. 10.1152\/ajpgi.00125.2021","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.03.214","article-title":"American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: pharmacological management of chronic idiopathic constipation","volume":"164","author":"Chang L","year":"2023","unstructured":"Chang L, Chey WD, Imdad A, et al.. American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: pharmacological management of chronic idiopathic constipation. Gastroenterology. 2023, 164:1086-106. 10.1053\/j.gastro.2023.03.214","journal-title":"Gastroenterology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2014.195","article-title":"The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis","volume":"109","author":"Moayyedi P","year":"2014","unstructured":"Moayyedi P, Quigley EM, Lacy BE, et al.. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2014, 109:1367-74. 10.1038\/ajg.2014.195","journal-title":"Am J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/NT.0000000000000489","article-title":"Psyllium: the gel-forming nonfermented isolated fiber that delivers multiple fiber-related health benefits","volume":"56","author":"McRorie JW Jr","year":"2021","unstructured":"McRorie JW Jr, Gibb RD, Sloan KJ, McKeown NM. Psyllium: the gel-forming nonfermented isolated fiber that delivers multiple fiber-related health benefits. Nutr Today. 2021, 56:169-82 . 10.1097\/NT.0000000000000489","journal-title":"Nutr Today"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.5152\/tjg.2020.20229","article-title":"Inflammation in irritable bowel syndrome (IBS): role of psyllium fiber supplementation in decreasing inflammation and physiological management of IBS","volume":"32","author":"Garg P","year":"2021","unstructured":"Garg P. Inflammation in irritable bowel syndrome (IBS): role of psyllium fiber supplementation in decreasing inflammation and physiological management of IBS. Turk J Gastroenterol. 2021, 32:108-10. 10.5152\/tjg.2020.20229","journal-title":"Turk J Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000488695","article-title":"Medical therapy of constipation: current standards and beyond","volume":"34","author":"Andresen V","year":"2018","unstructured":"Andresen V, Layer P. Medical therapy of constipation: current standards and beyond. Visc Med. 2018, 34:123-7. 10.1159\/000488695","journal-title":"Visc Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.5694\/mja18.00241","article-title":"Chronic idiopathic constipation in adults: epidemiology, pathophysiology, diagnosis and clinical management","volume":"209","author":"Black CJ","year":"2018","unstructured":"Black CJ, Ford AC. Chronic idiopathic constipation in adults: epidemiology, pathophysiology, diagnosis and clinical management. Med J Aust. 2018, 209:86-91. 10.5694\/mja18.00241","journal-title":"Med J Aust"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.21166","article-title":"Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder","volume":"120","author":"Bouras EP","year":"2001","unstructured":"Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology. 2001, 120:354-60. 10.1053\/gast.2001.21166","journal-title":"Gastroenterology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2165\/11204000-000000000-00000","article-title":"Prucalopride","volume":"69","author":"Frampton JE","year":"2009","unstructured":"Frampton JE. Prucalopride. Drugs. 2009, 69:2463-76. 10.2165\/11204000-000000000-00000","journal-title":"Drugs"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-009-1068-x","article-title":"Efficacy and safety of lubiprostone in patients with chronic constipation","volume":"55","author":"Barish CF","year":"2010","unstructured":"Barish CF, Drossman D, Johanson JF, Ueno R. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci. 2010, 55:1090-7. 10.1007\/s10620-009-1068-x","journal-title":"Dig Dis Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03881.x","article-title":"Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies","volume":"29","author":"Drossman DA","year":"2009","unstructured":"Drossman DA, Chey WD, Johanson JF, Fass R, Scott C, Panas R, Ueno R. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009, 29:329-41. 10.1111\/j.1365-2036.2008.03881.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-2803.202000000-83","article-title":"Systematic review with meta-analysis: lubiprostone efficacy on the treatment of patients with constipation","volume":"57","author":"Passos MD","year":"2020","unstructured":"Passos MD, Takemoto ML, Corradino GC, Guedes LS. Systematic review with meta-analysis: lubiprostone efficacy on the treatment of patients with constipation. Arq Gastroenterol. 2020, 57:498-506. 10.1590\/S0004-2803.202000000-83","journal-title":"Arq Gastroenterol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.70070","article-title":"The efficacy of lubiprostone in patients of constipation: an\u00a0updated systematic review and meta-analysis","volume":"9","author":"Akram U","year":"2025","unstructured":"Akram U, Rehman OU, Fatima E, et al.. The efficacy of lubiprostone in patients of constipation: an\u00a0updated systematic review and meta-analysis. JGH Open. 2025, 9:e70070. 10.1002\/jgh3.70070","journal-title":"JGH Open"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04983.x","article-title":"Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation","volume":"35","author":"Chey WD","year":"2012","unstructured":"Chey WD, Drossman DA, Johanson JF, Scott C, Panas RM, Ueno R. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2012, 35:587-99. 10.1111\/j.1365-2036.2011.04983.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316029","article-title":"Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders","volume":"67","author":"Waldman SA","year":"2018","unstructured":"Waldman SA, Camilleri M. Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. Gut. 2018, 67:1543-52. 10.1136\/gutjnl-2018-316029","journal-title":"Gut"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010863","article-title":"Two randomized trials of linaclotide for chronic constipation","volume":"365","author":"Lembo AJ","year":"2011","unstructured":"Lembo AJ, Schneier HA, Shiff SJ, et al.. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011, 365:527-36. 10.1056\/NEJMoa1010863","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002064","article-title":"Linaclotide reduced response time for irritable bowel syndrome with constipation symptoms: analysis of 4 randomized controlled trials","volume":"118","author":"Brenner DM","year":"2023","unstructured":"Brenner DM, Lacy BE, Ford AC, et al.. Linaclotide reduced response time for irritable bowel syndrome with constipation symptoms: analysis of 4 randomized controlled trials. Am J Gastroenterol. 2023, 118:872-9. 10.14309\/ajg.0000000000002064","journal-title":"Am J Gastroenterol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2019.1575203","article-title":"Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled phase 3 analysis","volume":"13","author":"Nee JW","year":"2019","unstructured":"Nee JW, Johnston JM, Shea EP, et al.. Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled phase 3 analysis. Expert Rev Gastroenterol Hepatol. 2019, 13:397-406. 10.1080\/17474124.2019.1575203","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2010.03.015","article-title":"Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract","volume":"86","author":"Bryant AP","year":"2010","unstructured":"Bryant AP, Busby RW, Bartolini WP, et al.. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci. 2010, 86:760-5. 10.1016\/j.lfs.2010.03.015","journal-title":"Life Sci"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00398-9","article-title":"Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"9","author":"Di Lorenzo C","year":"2024","unstructured":"Di Lorenzo C, Khlevner J, Rodriguez-Araujo G, et al.. Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Gastroenterol Hepatol. 2024, 9:238-50. 10.1016\/S2468-1253(23)00398-9","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref31","article-title":"Linaclotide","author":"Kalola UK","year":"2024","unstructured":"Kalola UK, Patel P, Chowdhury YS. Linaclotide. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.611","article-title":"A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation","volume":"112","author":"Miner PB Jr","year":"2017","unstructured":"Miner PB Jr, Koltun WD, Wiener GJ, et al.. A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation. Am J Gastroenterol. 2017, 112:613-21. 10.1038\/ajg.2016.611","journal-title":"Am J Gastroenterol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X17734697","article-title":"Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation","volume":"10","author":"DeMicco M","year":"2017","unstructured":"DeMicco M, Barrow L, Hickey B, Shailubhai K, Griffin P. Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation. Therap Adv Gastroenterol. 2017, 10:837-51. 10.1177\/1756283X17734697","journal-title":"Therap Adv Gastroenterol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0026-7","article-title":"Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials","volume":"113","author":"Brenner DM","year":"2018","unstructured":"Brenner DM, Fogel R, Dorn SD, et al.. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. Am J Gastroenterol. 2018, 113:735-45. 10.1038\/s41395-018-0026-7","journal-title":"Am J Gastroenterol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S400431","article-title":"Plecanatide improves symptoms of irritable bowel syndrome with constipation: results of an integrated efficacy and safety analysis of two phase 3 trials","volume":"16","author":"Brenner DM","year":"2023","unstructured":"Brenner DM, Dorn SD, Fogel RP, Christie J, Laitman AP, Rosenberg J. Plecanatide improves symptoms of irritable bowel syndrome with constipation: results of an integrated efficacy and safety analysis of two phase 3 trials. Int J Gen Med. 2023, 16:3769-77. 10.2147\/IJGM.S400431","journal-title":"Int J Gen Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1635792","article-title":"A pharmacovigilance study of the association between linaclotide\/plecanatide and muscle spasms based on food and drug administration adverse event reporting system","volume":"16","author":"Fan X","year":"2025","unstructured":"Fan X, Li Y, Lin X. A pharmacovigilance study of the association between linaclotide\/plecanatide and muscle spasms based on food and drug administration adverse event reporting system. Front Pharmacol. 2025, 16:1635792. 10.3389\/fphar.2025.1635792","journal-title":"Front Pharmacol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1159\/000371670","article-title":"Bile acids as hormones: the FXR-FGF15\/19 pathway","volume":"33","author":"Kliewer SA","year":"2015","unstructured":"Kliewer SA, Mangelsdorf DJ. Bile acids as hormones: the FXR-FGF15\/19 pathway. Dig Dis. 2015, 33:327-31. 10.1159\/000371670","journal-title":"Dig Dis"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.06.039","article-title":"Bile acid deficiency in a subgroup of patients with irritable bowel syndrome with constipation based on biomarkers in serum and fecal samples","volume":"16","author":"Vijayvargiya P","year":"2018","unstructured":"Vijayvargiya P, Busciglio I, Burton D, Donato L, Lueke A, Camilleri M. Bile acid deficiency in a subgroup of patients with irritable bowel syndrome with constipation based on biomarkers in serum and fecal samples. Clin Gastroenterol Hepatol. 2018, 16:522-7. 10.1016\/j.cgh.2017.06.039","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30123-7","article-title":"Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial","volume":"3(8)","author":"Nakajima A","year":"2018","unstructured":"Nakajima A, Seki M, Taniguchi S, Ohta A, Gillberg PG, Mattsson JP, Camilleri M. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. Lancet Gastroenterol Hepatol. 2018, 3(8):537-47. 10.1016\/S2468-1253(18)30123-7","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.23922\/jarc.2020-006","article-title":"Efficacy and safety of elobixibat in elderly patients with chronic constipation: a single-centre, observational study","volume":"4","author":"Abe T","year":"2020","unstructured":"Abe T, Kunimoto M, Hachiro Y, Ohara K, Inagaki M, Murakami M. Efficacy and safety of elobixibat in elderly patients with chronic constipation: a single-centre, observational study. J Anus Rectum Colon. 2020, 4:122-7. 10.23922\/jarc.2020-006","journal-title":"J Anus Rectum Colon"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S384251","article-title":"Tenapanor in the treatment of irritable bowel syndrome with constipation: discovery, efficacy, and role in management","volume":"16","author":"Herekar A","year":"2023","unstructured":"Herekar A, Shimoga D, Jehangir A, Shahsavari D, Yan Y, Karunaratne TB, Sharma A. Tenapanor in the treatment of irritable bowel syndrome with constipation: discovery, efficacy, and role in management. Clin Exp Gastroenterol. 2023, 16:79-85. 10.2147\/CEG.S384251","journal-title":"Clin Exp Gastroenterol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000516","article-title":"Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 12-week, placebo-controlled phase 3 trial (T3MPO-1)","volume":"115","author":"Chey WD","year":"2020","unstructured":"Chey WD, Lembo AJ, Rosenbaum DP. Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 12-week, placebo-controlled phase 3 trial (T3MPO-1). Am J Gastroenterol. 2020, 115:281-93. 10.14309\/ajg.0000000000000516","journal-title":"Am J Gastroenterol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001056","article-title":"Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 26-week, placebo-controlled phase 3 trial (T3MPO-2)","volume":"116","author":"Chey WD","year":"2021","unstructured":"Chey WD, Lembo AJ, Yang Y, Rosenbaum DP. Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 26-week, placebo-controlled phase 3 trial (T3MPO-2). Am J Gastroenterol. 2021, 116:1294-303. 10.14309\/ajg.0000000000001056","journal-title":"Am J Gastroenterol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.5009\/gnl19999","article-title":"Comparison of effectiveness between abdominal vibration stimulation and walking exercise for bowel cleansing before therapeutic colonoscopy","volume":"14","author":"Noh CK","year":"2020","unstructured":"Noh CK, Kim IS, Lee GH, et al.. Comparison of effectiveness between abdominal vibration stimulation and walking exercise for bowel cleansing before therapeutic colonoscopy. Gut Liver. 2020, 14:468-76. 10.5009\/gnl19999","journal-title":"Gut Liver"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.02.013","article-title":"Randomized placebo-controlled phase 3 trial of vibrating capsule for chronic constipation","volume":"164","author":"Rao SS","year":"2023","unstructured":"Rao SS, Quigley EM, Chey WD, Sharma A, Lembo AJ. Randomized placebo-controlled phase 3 trial of vibrating capsule for chronic constipation. Gastroenterology. 2023, 164:1202-1210.e6. 10.1053\/j.gastro.2023.02.013","journal-title":"Gastroenterology"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101407","article-title":"Efficacy and safety of vibrating capsule for functional constipation (VICONS): a randomised, double-blind, placebo-controlled, multicenter trial","volume":"47","author":"Zhu JH","year":"2022","unstructured":"Zhu JH, Qian YY, Pan J, et al.. Efficacy and safety of vibrating capsule for functional constipation (VICONS): a randomised, double-blind, placebo-controlled, multicenter trial. EClinicalMedicine. 2022, 47:101407. 10.1016\/j.eclinm.2022.101407","journal-title":"EClinicalMedicine"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.25122\/jml-2023-1025","article-title":"Vibrating colon-stimulating capsule to treat chronic constipation: a systematic review","volume":"16","author":"Math PB","year":"2023","unstructured":"Math PB, Ravi R, Hakami T, Das S, Patel N. Vibrating colon-stimulating capsule to treat chronic constipation: a systematic review. J Med Life. 2023, 16:1050-6. 10.25122\/jml-2023-1025","journal-title":"J Med Life"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.12485","article-title":"Safety and efficacy of the vibrating capsule, an innovative non-pharmacological treatment modality for chronic constipation","volume":"27","author":"Ron Y","year":"2015","unstructured":"Ron Y, Halpern Z, Safadi R, Dickman R, Dekel R, Sperber AD. Safety and efficacy of the vibrating capsule, an innovative non-pharmacological treatment modality for chronic constipation. Neurogastroenterol Motil. 2015, 27:99-104. 10.1111\/nmo.12485","journal-title":"Neurogastroenterol Motil"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2022.2150076","article-title":"Pharmacotherapeutic advances for chronic idiopathic constipation in adults","volume":"23","author":"Bassotti G","year":"2022","unstructured":"Bassotti G, Usai Satta P, Berti G, Lai M, Villanacci V, Bellini M. Pharmacotherapeutic advances for chronic idiopathic constipation in adults. Expert Opin Pharmacother. 2022, 23:2053-78. 10.1080\/14656566.2022.2150076","journal-title":"Expert Opin Pharmacother"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmr.2024.100021","article-title":"Beyond the stomach stall: current and emerging pharmacotherapeutics for gastroparesis","volume":"77","author":"Eid AH","year":"2025","unstructured":"Eid AH. Beyond the stomach stall: current and emerging pharmacotherapeutics for gastroparesis. Pharmacol Rev. 2025, 77:100021. 10.1016\/j.pharmr.2024.100021","journal-title":"Pharmacol Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/426873-pharmacotherapy-for-chronic-idiopathic-constipation-and-constipation-predominant-irritable-bowel-syndrome-beyond-conventional-laxatives-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T03:44:36Z","timestamp":1763869476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/426873-pharmacotherapy-for-chronic-idiopathic-constipation-and-constipation-predominant-irritable-bowel-syndrome-beyond-conventional-laxatives-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":50,"URL":"https:\/\/doi.org\/10.7759\/cureus.97523","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,22]]}}}